Vestibular schwannomas (VSs) are benign tumors of the eighth cranial nerve. Although Gamma Knife radiosurgery (GKRS) achieves durable tumor control, delayed regression and pseudoprogression remain clinical challenges. Staged GKRS combined with bevacizumab may alter post-radiosurgical tumor response patterns....
✦ The floor
Discussion
Signed responses from readers of the wire.
No immediate change to audiology practice, but findings are relevant for audiologists co-managing vestibular schwannoma patients undergoing combined radiosurgery and anti-angiogenic drug therapy.
Vestibular schwannomas directly affect hearing and balance, and understanding how combination treatments change tumor dynamics over time can inform audiological monitoring protocols and counseling.
- 01Longitudinal study of sporadic vestibular schwannoma patients treated with staged Gamma Knife radiosurgery plus bevacizumab.
- 02Tracks tumor response dynamics over time rather than a single post-treatment snapshot.
- 03Bevacizumab is an anti-angiogenic drug sometimes used for schwannoma-related growth control.
- 04Results relevant to audiologists monitoring hearing and tumor status in these patients.
- 05Published in Clinical and Translational Radiation Oncology.
Staged Gamma Knife radiosurgery combined with bevacizumab produces measurable longitudinal tumor response in sporadic vestibular schwannoma.
studypartially supported- PMID
- 42936495
- DOI
- 10.1016/j.ctro.2026.101318.
- Journal
- Clinical and Translational Radiation Oncology
- Publication type
- research_article
- Evidence level
- 4
- Population
- Patients with sporadic vestibular schwannoma
- Intervention
- Staged Gamma Knife radiosurgery combined with bevacizumab
Primary outcomes
Longitudinal tumor response dynamics; Tumor volume change over time